MBC was more prevalent among participants with more aggressive tumor features, including grade 3 vs grade 1 (OR = 4.15, 95% CI: 2.60, 6.99), LumB vs LumA (OR = 2.08, 95% CI: 1.48, 2.90), HER2-encriched vs LumA (OR = 2.13, 95% CI: 1.45, 3.12), Basal-like vs LumA (OR = 1.42, 95% CI: 1.03, 1.96), mutant p53 vs wildtype (OR = 1.45, 95% CI: 1.14, 1.84), and HRD-high vs -low (OR = 1.61, 95% CI: 1.27, 2.05), high vs low ROR-PT (OR = 4.45, 95% CI: 2.93, 6.99). This evidence concerns the gene TP53 and neoplasm.